Heartseed Inc. (TYO:219A)

Japan flag Japan · Delayed Price · Currency is JPY
1,900.00
+118.00 (6.62%)
Mar 5, 2026, 3:30 PM JST
Market Cap40.73B +11.3%
Revenue (ttm)3.03B +777.9%
Net Income592.50M
EPS25.71
Shares Out22.86M
PE Ratio69.31
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume445,000
Average Volume376,030
Open1,862.00
Previous Close1,782.00
Day's Range1,844.00 - 1,940.00
52-Week Range1,343.00 - 4,385.00
Betan/a
RSI39.35
Earnings DateFeb 13, 2026

About Heartseed

Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company’s lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. The company was incorporated in 2015 and is headquartered in Tokyo, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2015
Country Japan
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 219A
Full Company Profile

Financial Performance

Financial Statements